Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin - Wikidata - wikimedia - TriplyDB

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

http://www.wikidata.org/entity/Q29619238

about

Stem cell sources for tooth regeneration: current status and future prospects Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells Direct cell reprogramming is a stochastic process amenable to acceleration Metastable pluripotent states in NOD-mouse-derived ESCs Totipotency, pluripotency and nuclear reprogramming Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis iPSCs: A Minireview from Bench to Bed, including Organoids and the CRISPR System Cellular reprogramming in farm animals: an overview of iPSC generation in the mammalian farm animal species Modeling Kidney Disease with iPS Cells Hematopoietic stem cell expansion and generation: the ways to make a breakthrough An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs Prospects and Challenges of Induced Pluripotent Stem Cells in Equine Health Advanced cell therapies: targeting, tracking and actuation of cells with magnetic particles Research on induced pluripotent stem cells and the application in ocular tissues Applications of iPSCs in Cancer Research Mesenchymal Stromal Cells Affect Disease Outcomes via Macrophage Polarization New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals Induced pluripotent stem cell technology for dissecting the cancer epigenome Advancements in stem cells treatment of skeletal muscle wasting Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies Induced pluripotent stem cell technology and direct conversion: new possibilities to study and treat Parkinson's disease Stem cells: update and impact on craniofacial surgery Pluripotent stem cells in research and treatment of hemoglobinopathies Dedifferentiation and reprogramming: origins of cancer stem cells Pluripotent stem cells and gene therapy Induction of pluripotency by defined factors Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells.The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies Reprogramming cells with synthetic proteins Advances in cellular technology in the hematology field: What have we learned so far?Current status of induced pluripotent stem cells in cardiac tissue regeneration and engineering iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery Induced pluripotent stem cells as a disease modeling and drug screening platform Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application Stem cell transplantation for motor neuron disease: current approaches and future perspectives

P2860

Q21129232-D136A580-4272-42D8-B849-448815CF6F26 Q21183968-93C9CF86-C31F-4DA1-86DC-3BA5A5A582D8 Q24321371-75C582DE-108A-4EE6-A5C9-068575E2F2C3 Q24617141-62164D55-9EBC-4F56-9CE8-5DC465322B60 Q24634829-2677C55E-F8F1-46ED-B95D-9CB298B9D697 Q24644898-DFE6DE51-487D-4010-BB8F-254CB3FC1057 Q24645721-31B9F10B-6CDB-472F-B302-8033B9E308C0 Q24646675-2F30E6DB-5FD0-4EA9-9655-3BD80AA04472 Q24653753-3754276E-921D-4736-9317-DE2D795D7162 Q26753109-AE5D6D81-9881-4E19-996D-87E89BFBC384 Q26765886-86F9E9BB-1A04-4C5E-A89B-091BD398205E Q26768505-BFA3D753-365A-4D4D-B1D8-530DCFF79EDE Q26770384-4E0D5A86-3D88-4AC9-BF71-8037562BF6E2 Q26771763-10335B90-B4FB-4586-8294-8AE939A48C49 Q26775122-7B3E46D7-638F-4B41-8CE7-E5F7F337DA47 Q26776053-AE2A6351-0358-4042-81C8-CB5A95243551 Q26782710-7DE5DD9E-853F-4BBC-8F34-9D7B5E83DFC5 Q26796711-677F3410-9FCD-4D8E-B2B4-9FE88079BE02 Q26798036-BDE7AD1C-8738-479F-A879-20996A772674 Q26800098-2FA5EF44-4927-471B-9431-B46C92FBC9B3 Q26801582-946BB3D6-A4C4-4BC2-9B05-68642765CAE0 Q26801711-B760E009-E78B-4DDD-9A65-F9A415DF0A46 Q26822437-22DEC0A9-CC6D-495B-BD78-D6C4F218CC07 Q26822810-F21845D5-6D10-41A8-97FE-9BD9436F0923 Q26823333-3B896889-8807-4005-B86E-8F5A867D74C0 Q26824134-67196683-5DE3-43AB-AE8A-BFAA74D1AA98 Q26825713-126752DE-F2C4-4B69-ACCC-F6696F549DDF Q26826876-4E2002A2-E283-48BF-8377-FDE45A14D61A Q26827643-5283902C-DA6B-415D-AF62-967E3F79F54E Q26830425-871A5213-E034-4E92-8E08-76E282E40360 Q26849530-D57829F6-9BA4-4231-9EE5-E79490A86E06 Q26851475-9E85C9D4-0226-4CAD-94CB-977F57068B62 Q26851666-5FFC1F0E-1A1C-43F2-A60F-6FCD5CDAD663 Q26853155-DEB7F982-B311-4D68-A300-D293CCDC087B Q26853179-3BA628E9-10E9-4884-8304-6C4631C773EC Q26863381-E752A976-CC8C-463E-86B1-ECA0EBB54BF8 Q26865055-9F834C23-40D7-444B-BB3C-BA75AE6B71C2 Q26865689-880E6273-2D48-45A7-A8F0-7263CB32540B Q26866409-9690F566-7F6D-4731-BAF0-03DEA810B061 Q26995278-558540BE-64B2-4CCD-A03E-2B1F684AB97E

P2860

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

http://www.wikidata.org/entity/Q29619238

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

@ast

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

@en

type

label

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

@ast

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

@en

prefLabel

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

@ast

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

@en

P1433

Q29619238-19CC8009-00E3-44FB-8938-AC6ECBDDF731

P1476

Q29619238-F9E14B8A-E1E5-459A-9F07-F8CC4708001E

P2093

Q29619238-066E03CC-F97E-49A4-B190-8A18B26F6220

Q29619238-2159A4DE-1E4A-46A7-8A63-D3D70B124A34

Q29619238-2562B49E-4FEF-4237-8A27-D8B00B1DD658

Q29619238-3846555D-2C2F-48F5-8C42-6D6D68F20AC6

Q29619238-3CAB24E6-5E61-4691-9471-45D60B701DC2

Q29619238-4888DE51-36AE-48F5-B6E1-DA14417FDFB9

Q29619238-4BB52071-8475-46CE-8C5C-EB5B26B9FFD5

Q29619238-93A0E50A-22D3-448C-A700-07E507628E6E

Q29619238-9DDBA846-2FC6-4321-AE5B-648DB14F59F3

Q29619238-FD69E254-C610-4F31-BE76-DB610A84A28E

P2860

Q29619238-3BBFDE59-72F4-491C-A721-C3BADD4E4467

Q29619238-5F0A9CF6-7963-4374-8C28-76982F703D8E

Q29619238-795A2C44-6104-4B97-A931-04C7BE498FA6

Q29619238-908A10F1-157A-44E8-932C-E4D666CD15E1

Q29619238-CF17D413-D188-409A-B51B-4F7099A9C751

Q29619238-E24802C6-984E-40C4-A6FA-30D1F507F21D

P304

Q29619238-83CBFB27-1CFE-4923-AD4B-CB283D85D6E9

P31

Q29619238-2C87E6F2-440C-4E55-8CA8-68B66773BE5E

P3181

Q29619238-1AA4270E-6AD0-4F1D-9140-0E66C5BFE957

P356

Q29619238-4DAD0BF2-D383-4A4E-AD0A-CF6969488A89

P407

Q29619238-63BCB6FD-9CE7-4A6A-AEB9-0CD68064522B

P433

Q29619238-408F9861-3218-418B-9A3F-5D7345B62294

P478

Q29619238-2FFDB744-DA0A-4D55-B9DE-91C8F26E984D

P50

Q29619238-9F4B44F8-6C71-4345-87B6-7878E89B572A

P577

Q29619238-02639E6D-9181-4B4E-AD91-0AC2E70314D5

P5875

Q29619238-36F5768D-C1FD-4FAC-8AEF-848F468CC053

P698

Q29619238-D57C7328-0186-49CC-90DF-D0B7B561616C

P921

Q29619238-018E8928-AC8C-4DE9-8EEF-44831B5782CE

P3181

P356

SCIENCE.1152092

P1433

P1476

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

@en

P2093

Beard C

http://www.w3.org/2001/XMLSchema#string

Brambrink T

http://www.w3.org/2001/XMLSchema#string

Cassady JP

http://www.w3.org/2001/XMLSchema#string

Hanna J

http://www.w3.org/2001/XMLSchema#string

Markoulaki S

http://www.w3.org/2001/XMLSchema#string

Meissner A

http://www.w3.org/2001/XMLSchema#string

Sun CW

http://www.w3.org/2001/XMLSchema#string

Townes TM

http://www.w3.org/2001/XMLSchema#string

Wernig M

http://www.w3.org/2001/XMLSchema#string

Wu LC

http://www.w3.org/2001/XMLSchema#string

P2860

Induced pluripotent stem cell lines derived from human somatic cells

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

Generation of germline-competent induced pluripotent stem cells

Nuclear reprogramming and pluripotency

In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state

P304

1920-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1105130

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1152092

http://www.w3.org/2001/XMLSchema#string

P407

P433

5858

http://www.w3.org/2001/XMLSchema#string

P478

318

http://www.w3.org/2001/XMLSchema#string

P50

Rudolf Jaenisch

P577

2007-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5784072

http://www.w3.org/2001/XMLSchema#string

P698

18063756

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease